UPDATE: Moderna (MRNA) PT Raised to 'Street High' $105 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Price: $237.18 -3.51%
Rating Summary:
7 Buy, 20 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Rating Summary:
7 Buy, 20 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Join SI Premium – FREE
(Updated - May 18, 2020 10:00 AM EDT)
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and raised his price target on Moderna (NASDAQ: MRNA) to $105.00 (from $63.00) following positive COVID vaccine data.
The price target is a new 'Street High'.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $66.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crown Castle (CCI) PT Lowered to $91 at BMO Capital Following Mixed Results
- Lam Research (LRCX) PT Lowered to $350 at Bernstein SocGen Group
- U.S. signs Lockheed Martin deal for minimum of 850 F-35 jets
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot Comments, Momentum Movers, Trader TalkRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
